A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer

BACKGROUND: Eribulin is a microtubule dynamics inhibitor with a novel mechanism of action. This phase 3 study aimed to compare overall survival (OS) in patients with heavily pretreated non-small cell lung cancer (NSCLC) receiving eribulin to treatment of physician’s choice (TPC). PATIENTS AND METHOD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Katakami, N., Felip, E., Spigel, D. R., Kim, J.-H., Olivo, M., Guo, M., Nokihara, H., Yang, J. C.-H., Iannotti, N., Satouchi, M., Barlesi, F.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834051/
https://ncbi.nlm.nih.gov/pubmed/28911085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx284
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados